BIP
TEVA icon

Brandes Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Brandes Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,600
Closed -$224K – 197
2015
Q1 		$224K Hold
3,600
– – ﹤0.01% 141
2014
Q4 		$207K Buy
+3,600
New +$201K ﹤0.01% 145

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Brandes Investment Partners's TEVA Position: Q2 2015 in Review

Brandes Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 3,600 shares — an estimated $224K sold.

Brandes Investment Partners first reported a position in TEVA in Q4 2014 and held it in 2 quarters. The position peaked at $224K in Q1 2015. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • Brandes Investment Partners reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Brandes Investment Partners sold 3,600 Teva Pharmaceuticals shares in Q2 2015, an estimated $224K.
  • Brandes Investment Partners first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Brandes Investment Partners's Teva Pharmaceuticals position peaked at $224K in Q1 2015.
  • 819 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Brandes Investment Partners's 13F filing for Q2 2015, filed 10 Aug 2015.